SELECT id, `name`, primary_key, `key`, treemapgroup, name_cn, zacks_table_name, compare_key, compare_display_name from gurufocu_main.financial_definition where termpagedisplay=1 and `key` = 'sloanratio' DVA (DaVita) Sloan Ratio %
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (NYSE:DVA) » Definitions » Sloan Ratio %

DaVita (DaVita) Sloan Ratio %

: -3.53% (As of Dec. 2023)
View and export this data going back to 1995. Start your Free Trial

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

DaVita's Sloan Ratio for the quarter that ended in Dec. 2023 was -3.53%.

As of Dec. 2023, DaVita has a Sloan Ratio of -3.53%, indicating the company is in the safe zone and there is no funny business with accruals.


DaVita Sloan Ratio % Historical Data

The historical data trend for DaVita's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DaVita Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.59 -2.24 -0.98 -2.21 -3.53

DaVita Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.21 -3.36 -3.94 -2.91 -3.53

Competitive Comparison

For the Medical Care Facilities subindustry, DaVita's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DaVita Sloan Ratio % Distribution

For the Healthcare Providers & Services industry and Healthcare sector, DaVita's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where DaVita's Sloan Ratio % falls into.



DaVita Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

DaVita's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(691.535-2059.031
--771.8)/16893.578
=-3.53%

DaVita's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(691.535-2059.031
--771.8)/16893.578
=-3.53%

DaVita's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was 115.547 (Mar. 2023 ) + 178.691 (Jun. 2023 ) + 246.632 (Sep. 2023 ) + 150.665 (Dec. 2023 ) = $692 Mil.
DaVita's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was 462.557 (Mar. 2023 ) + 450.107 (Jun. 2023 ) + 661.162 (Sep. 2023 ) + 485.205 (Dec. 2023 ) = $2,059 Mil.
DaVita's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -116.544 (Mar. 2023 ) + -347.113 (Jun. 2023 ) + -139.847 (Sep. 2023 ) + -168.296 (Dec. 2023 ) = $-772 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DaVita  (NYSE:DVA) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, DaVita has a Sloan Ratio of -3.53%, indicating the company is in the safe zone and there is no funny business with accruals.


DaVita Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of DaVita's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


DaVita (DaVita) Business Description

Traded in Other Exchanges
Address
2000 16th Street, Denver, CO, USA, 80202
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Executives
Christopher Michael Berry officer: Chief Accounting Officer C/O SONDER HOLDINGS INC., 101 15TH ST., SAN FRANCISCO CA 94103
Kathleen Alyce Waters officer: Chief Legal Officer C/O DAVITA INC., 2000 16TH STREET, DENVER CO 80202
Wendy Lee Schoppert director 6105 TRENTON LANE NORTH, MINNEAPOLIS MN 55442
Phyllis R Yale director
Javier Rodriguez officer: Chief Executive Officer, DKC 601 HAWAII ST., EL SEGUNDO CA 90245
Barbara J Desoer director CITIGROUP INC., 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
James O Hearty officer: Chief Compliance Officer 2000 16TH STREET, DENVER CO 80202
Charles Berg director, officer: Executive Chair, DMG 48 MONROE TURNPIKE, TRUMBULL CT 06611
John M Nehra director 1119 ST PAUL ST, BALTIMORE MD 21202
Adam H Schechter director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Michael David Staffieri officer: Chief Operating Officer, DKC 2000 16TH STREET, DENVER CO 80202
Jason M. Hollar director 3333 BEVERLY ROAD, HOFFMAN ESTATES IL 60179
Paula A Price director ONE CVS DRIVE, WOONSOCKET RI 02895
Pamela M Arway director 601 HAWAII ST., EL SEGUNDO CA 90245
Gregory J. Moore director 130 EAST RANDOLPH STREET, SUITE 1000, CHICAGO IL 60601

DaVita (DaVita) Headlines

From GuruFocus

Q2 2023 DaVita Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2020 DaVita Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2023 DaVita Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2020 DaVita Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2022 DaVita Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2022 DaVita Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2021 DaVita Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2022 DaVita Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024